Eli Lilly’s Taltz Wins Second NMPA Approval for Ankylosing Spondylitis
U.S. pharmaceutical giant Eli Lilly announced it has received a second marketing approval from the...
China Resources Double-Crane to Acquire Stake in Shenzhou Biotech for Bio-Fermentation Push
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced plans to acquire a 50.11% stake...
Coherent Biopharma Raises Series B Funds to Advance Bi-XDC Pipeline
Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), has reportedly raised an...
Hengrui Medicine’s Pyrotinib Combo Meets Endpoints in HER2+ Breast Cancer Trial
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its tyrosine kinase inhibitor (TKI) pyrotinib,...
Shouyao Holdings Receives Approval for CT-3505 ALK Inhibitor Study in NSCLC
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced it has received ethical approval from...
InnoCare Pharma Doses First Patient in ICP-488 Study for Autoimmune Diseases
China-based InnoCare Pharma (HKG: 9969) announced that the first subject has been dosed in a...
Convalife Pharmaceuticals Licenses Karus Therapeutics’ CVL237 Globally
Shanghai-based Convalife Pharmaceuticals has entered into a licensing agreement with UK-based Karus Therapeutics Ltd, acquiring...
Unicycive Therapeutics Licenses Renazorb to Lee’s Pharma for Asian Markets
U.S.-based biotech Unicycive Therapeutics, Inc. (NASDAQ: UNCY) announced a licensing agreement with Hong Kong-listed Lee’s...
HutchMed Initiates China Bridging Study for Tazverik in Follicular Lymphoma
HutchMed (NASDAQ: HCM, HKG: 0013) announced the initiation of a bridging study for Tazverik (tazemetostat)...
Hainan Shuangcheng to Transfer Triptorelin Assets to Chongqing Lummy for USD 4.7M
Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) will transfer all tangible and intangible assets and...
Eccogene Receives FDA Approval for ECC4703 Phase I Study in NASH and Dyslipidemia
Shanghai-based biopharmaceutical company Eccogene announced it has received approval from the U.S. Food and Drug...
HutchMed’s H1 2022 Oncology Sales Surge 82% on Strong Product Performance
China-based biopharma HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) reported strong financial results for the...
Lion TCR Enrolls First Patient in LioCyx-M004 Study for HBV-Related Liver Cancer
Singapore-based clinical-stage biotech Lion TCR announced the enrollment of the first subject in a clinical...
Grand Pharma’s TLX591-CDx and TLX250-CDx Advance in China with NMPA Review
Grand Pharmaceutical Group Limited (HKG: 0512) announced that the National Medical Products Administration (NMPA) has...
OriginCell Therapeutics Raises USD 120M in Series B for Tumor Immunotherapy Pipeline
OriginCell Therapeutics, a Shanghai-based tumor immunotherapy specialist, reportedly raised over USD 120 million in a...
Fosun Pharma to Hike Aitrox Stake to 72.63% for USD 61M
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) plans to increase its ownership...
GluBio Pharma Raises USD 22M in Series A+ Round to Advance TPD Pipeline
GluBio Pharmaceutical Co., Ltd, a Zhejiang-based specialist in molecular glue targeted protein degradation (TPD), reportedly...
Ribo Life Science Raises USD 40M in Series E1 Round for siRNA Drug Development
China-based Suzhou Ribo Life Science Co., Ltd reportedly raised USD 40 million in a Series...
BridGene Biosciences Completes USD 38.5M Series B Round with China Funds
U.S.-based biotech BridGene Biosciences Inc. has completed a Series B financing round, raising USD 38.5...
Basecare Medical Sells 35% Stake in Cellpro Biotech for USD 9.5M
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based IVF specialist, will sell a 35%...